Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids

Glucose-dependent insulinotropic polypeptide (GIP) has been suggested to have direct effects on nonislet tissues. GIP also reportedly increased glucose uptake and inhibition of lipolysis in adipocytes after inhibition of the intracellular cortisone-cortisol shuttle 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). We here analyzed whether GIP modifies lipid metabolism and further elucidated the relation between GIP, 11β-HSD1, and fatty acid metabolism. GIP reduced activity of 11β-HSD1 promoter constructs and the expression and activity of 11β-HSD1 in differentiated 3T3-L1 adipocytes in a time- and dose-dependent fashion. This was paralleled by a reduction of free fatty acid (FFA) release and a reduced expression of key enzymes regulating lipolysis in adipose tissue. Preinhibition of 11β-HSD1 completely abolished GIP-induced effects on FFA release. To investigate the acute effects of GIP in humans, a randomized clinical trial was performed. GIP lowered circulating FFAs compared with saline control and reduced expression and ex vivo activity of 11β-HSD1 and adipose triglyceride lipase expression in subcutaneous fat biopsies. Our data suggest that GIP reduces FFA release from adipose tissue by inhibition of lipolysis or by increased reesterification. This process appears to depend on a modification of 11β-HSD1 activity. In general, the presented data support that GIP has direct and insulin-independent effects on adipose tissue.

[1]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans , 2010, Diabetes.

[2]  C. Rotella,et al.  Cardio Vascular Diabetology Open Access Original Investigation , 2022 .

[3]  J. Holst,et al.  Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. , 2010, Metabolism: clinical and experimental.

[4]  A. Astrup,et al.  On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. , 2010, American journal of physiology. Endocrinology and metabolism.

[5]  K. Svenson,et al.  Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. , 2009, Journal of medicinal chemistry.

[6]  M. Tschöp,et al.  Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice , 2009, Diabetologia.

[7]  S. Kahn,et al.  Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. , 2009, American journal of physiology. Endocrinology and metabolism.

[8]  Mark Ellrichmann,et al.  Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.

[9]  B. Corkey,et al.  Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. , 2007, Gastroenterology.

[10]  J. Holst,et al.  GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. , 2007, American journal of physiology. Endocrinology and metabolism.

[11]  A. Pfeiffer,et al.  Rosiglitazone decreases 11β‐hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue , 2007, Clinical Endocrinology.

[12]  A. Pfeiffer,et al.  GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women , 2007, Regulatory Peptides.

[13]  S. B. Pedersen,et al.  11β‐HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat Localization , 2007, Obesity.

[14]  Tanya Hansotia,et al.  Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. , 2007, The Journal of clinical investigation.

[15]  A. Pfeiffer,et al.  Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter , 2007, Archives of physiology and biochemistry.

[16]  B. Corkey,et al.  Glucose‐Dependent Insulinotropic Polypeptide Modulates Adipocyte Lipolysis and Reesterification , 2006, Obesity.

[17]  A. Pfeiffer,et al.  Changes of adiponectin oligomer composition by moderate weight reduction. , 2005, Diabetes.

[18]  C. Mcintosh,et al.  Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression* , 2005, Journal of Biological Chemistry.

[19]  H. Sul,et al.  Desnutrin, an Adipocyte Gene Encoding a Novel Patatin Domain-containing Protein, Is Induced by Fasting and Glucocorticoids , 2004, Journal of Biological Chemistry.

[20]  J. Flier,et al.  Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. , 2004, Diabetes.

[21]  L. Abrahmsén,et al.  Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. , 2003, Endocrinology.

[22]  J. Bunt,et al.  Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  L. Abrahmsén,et al.  Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice , 2002, Diabetologia.

[24]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[25]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[26]  J. Holst,et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. , 2001, Diabetes.

[27]  D. Hörsch,et al.  Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. , 2001, Molecular endocrinology.

[28]  M. Wolfe,et al.  GIP biology and fat metabolism. , 1999, Life sciences.

[29]  R. Pederson,et al.  Glucose-Dependent Insulinotropic Polypeptide Stimulation of Lipolysis in Differentiated 3T3-L1 Cells: Wortmannin-Sensitive Inhibition by Insulin* * This work was supported by grants from Zymogenetics Inc. (Seattle, WA), the Medical Research Council of Canada (5-90007-RAP/CHSM) and the Canadian Diabe , 1999, Endocrinology.

[30]  J. Karlsson,et al.  A method for protein assay in Laemmli buffer. , 1994, Analytical biochemistry.